INOVIO has licensed from UPenn exclusive worldwide rights to develop numerous DNA constructs with the potential to treat and/or prevent various cancers and infectious diseases.


In March 2016, INOVIO entered into collaborative research agreements with Wistar for preventive and therapeutic DNA-based immunotherapy applications and products developed by Dr. David Weiner and Wistar for the treatment of cancers and infectious diseases. INOVIO will have the exclusive right to in-license new intellectual property developed in these agreements.

In early 2018, INOVIO announced a collaboration with The Wistar Institute to advance two novel DNA vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4.6 million in total grants from the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH). Grants from the Gates Foundation (for malaria) and from the National Institute of Allergy & Infectious Diseases (for TB) will support our efforts to develop new DNA vaccines employing our DNA medicines technology platform.

In April 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) granted $6.9 million funding to INOVIO and the International Vaccine Institute (IVI) to conduct clinical testing of INOVIO’s COVID-19 DNA vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO’s Phase 1 INO-4800 study currently underway in the U.S.